DK1874781T3 - Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme - Google Patents

Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme

Info

Publication number
DK1874781T3
DK1874781T3 DK06743350T DK06743350T DK1874781T3 DK 1874781 T3 DK1874781 T3 DK 1874781T3 DK 06743350 T DK06743350 T DK 06743350T DK 06743350 T DK06743350 T DK 06743350T DK 1874781 T3 DK1874781 T3 DK 1874781T3
Authority
DK
Denmark
Prior art keywords
dihydrothienopyrimidines
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
DK06743350T
Other languages
Danish (da)
English (en)
Inventor
Pascale Pouzet
Christoph Hoenke
Peter Nickolaus
Birgit Jung
Domnic Martyres
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1874781T3 publication Critical patent/DK1874781T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D521/00—Heterocyclic compounds containing unspecified hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK06743350T 2006-04-19 2006-04-19 Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme DK1874781T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005019201A DE102005019201A1 (de) 2006-04-19 2006-04-19 Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
PCT/EP2006/061680 WO2006111549A1 (fr) 2005-04-21 2006-04-19 Dihydrothienopyrimidines destines au traitement de maladies inflammatoires

Publications (1)

Publication Number Publication Date
DK1874781T3 true DK1874781T3 (da) 2009-11-02

Family

ID=36678631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06743350T DK1874781T3 (da) 2006-04-19 2006-04-19 Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme

Country Status (28)

Country Link
US (3) US7511045B2 (fr)
EP (2) EP2060575A1 (fr)
JP (1) JP5021624B2 (fr)
KR (1) KR101335964B1 (fr)
CN (1) CN101163706A (fr)
AR (1) AR053235A1 (fr)
AT (1) ATE434620T1 (fr)
AU (1) AU2006237354B2 (fr)
BR (1) BRPI0608387A2 (fr)
CA (1) CA2605161A1 (fr)
CY (1) CY1109348T1 (fr)
DE (2) DE502006004066D1 (fr)
DK (1) DK1874781T3 (fr)
EA (1) EA013108B1 (fr)
ES (1) ES2328400T3 (fr)
HR (1) HRP20090395T1 (fr)
IL (1) IL186749A (fr)
MX (1) MX2007012313A (fr)
NO (1) NO20074615L (fr)
NZ (1) NZ563488A (fr)
PL (1) PL1874781T3 (fr)
PT (1) PT1874781E (fr)
RS (1) RS51163B (fr)
SI (1) SI1874781T1 (fr)
TW (1) TWI380984B (fr)
UA (1) UA93872C2 (fr)
WO (1) WO2006111549A1 (fr)
ZA (1) ZA200707591B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
JP2009528363A (ja) 2006-02-28 2009-08-06 ヘリコン セラピューティクス，インコーポレイテッド Ｐｄｅ４インヒビターとしての治療用ピペラジン
DE502006004066D1 (de) 2006-04-19 2009-08-06 Boehringer Ingelheim Pharma Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1847543A1 (fr) * 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidines pour le traitement de maladies inflammatoires
AU2008312624B2 (en) * 2007-10-18 2014-07-10 Boehringer Ingelheim International Gmbh Preparation of dihydrothieno [3, 2-D] pyrimidines and intermediates used therein
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
CA2705414C (fr) * 2007-10-19 2016-05-24 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidines substituees
WO2009050242A2 (fr) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Pipérazino-dihydrothiénopyrimidines substituées par un hétérocycle
EP2214673B1 (fr) * 2007-10-19 2012-05-30 Boehringer Ingelheim International GmbH Pipérazino-dihydrothiénopyrimidines phényl-substituées
CN101903372B (zh) 2007-12-21 2014-06-18 弗·哈夫曼-拉罗切有限公司 作为食欲肽受体拮抗剂的杂芳基衍生物
BRPI0906799A2 (pt) 2008-01-11 2015-07-14 Hoffmann La Roche Moduladores para amiloide beta
CA2713716A1 (fr) 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulateurs de la beta-amyloide
US8471010B2 (en) * 2008-05-13 2013-06-25 Boehringer Ingelheim International Gmbh Synthesis of dihydrothieno[3,2-d]pyrimidine diols
WO2010040661A1 (fr) 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Modulateurs pour l'amyloïde bêta
EP2355817A1 (fr) 2008-11-10 2011-08-17 F. Hoffmann-La Roche AG Modulateurs de la gamma secrétase hétérocyclique
JP2012513961A (ja) 2008-12-24 2012-06-21 シンジェンタ リミテッド 殺菌剤の調製方法
EP2400962B1 (fr) 2009-02-27 2017-11-08 Boehringer Ingelheim International GmbH Combinaisons de médicaments contenant des inhibiteurs PDE4 et NSAID
WO2010097332A1 (fr) 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Combinaisons de médicaments contenant des inhibiteurs de pde4 et des ains
UA107657C2 (uk) * 2009-03-10 2015-02-10 Такеда Фармасьютікал Компані Лімітед Похідні бензофурану
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US20140113877A1 (en) * 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
US9090624B2 (en) 2011-08-04 2015-07-28 Allergan, Inc. Aromatic bycyclic derivatives as CXCR4 receptor modulators
US9206195B2 (en) * 2011-08-09 2015-12-08 Boehringer Ingelheim International Gmbh Dihydrothienopyrimidines
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
GB201203266D0 (en) * 2012-02-24 2012-04-11 Randox Lab Ltd Assay for the detection of the phenylpiperazine family
US9499519B2 (en) 2012-12-26 2016-11-22 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
WO2014117947A1 (fr) 2013-02-04 2014-08-07 Grünenthal GmbH Composés pyrimidines condensés 4-amino substitués en tant qu'inhibiteurs de pde4
WO2014124860A1 (fr) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Inhibiteurs spécifiques de pde4b pour le traitement du diabète sucré
SG11201504709PA (en) 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as pde4 inhibitors
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN103893183B (zh) * 2014-03-12 2016-02-10 中山大学 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用
JP2018509377A (ja) * 2014-12-05 2018-04-05 サウザーン リサーチ インスチチュート 生体アミン輸送モジュレータとしてのヘテロ環式化合物
WO2019045824A1 (fr) 2017-09-01 2019-03-07 Kadmon Corporation, Llc Inhibiteurs de protéine kinase à superenroulement d'hélices alpha (« coiled-coil ») associée à rho
EP3684775A1 (fr) 2017-09-20 2020-07-29 Leo Pharma A/S Dihydrothiénopyrimidines substituées, et leur utilisation en tant qu'inhibiteurs de la phosphodiestérase
EA202090977A1 (ru) 2017-10-23 2020-09-04 Бёрингер Ингельхайм Интернациональ Гмбх Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild)
US11299497B2 (en) 2017-12-15 2022-04-12 UNION therapeutics A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
ES2935615T3 (es) 2017-12-15 2023-03-08 Union Therapeutics As Azetidina dihidrotienopiridinas sustituidas y su uso como inhibidores de la fosfodiesterasa
ES2968822T3 (es) 2017-12-15 2024-05-14 Union Therapeutics As Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa
CN111285882B (zh) * 2018-12-07 2022-12-02 四川科伦博泰生物医药股份有限公司 稠环化合物、包含其的药物组合物及其制备方法和用途
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
US20230181590A1 (en) 2021-12-09 2023-06-15 Boehringer Ingelheim International Gmbh New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
AU2022404695A1 (en) 2021-12-09 2024-05-02 Boehringer Ingelheim International Gmbh New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
WO2024032673A1 (fr) * 2022-08-09 2024-02-15 西藏海思科制药有限公司 Inhibiteur de pde4b et son utilisation
WO2024068386A1 (fr) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Utilisation de biomarqueurs dans le traitement d'états fibrotiques avec inhibiteur de la pde4b
WO2024067660A1 (fr) * 2022-09-29 2024-04-04 苏州爱科百发生物医药技术有限公司 Composé cyclique aza-fusionné, son procédé de préparation et son utilisation en médecine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) * 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL124131C (fr) * 1963-06-17
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE663693A (fr) 1965-03-31
DE2032687A1 (en) * 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
DE1940572A1 (de) * 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (fr) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) * 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
RO62428A (fr) * 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
DE2750288A1 (de) * 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US4265738A (en) * 1979-10-25 1981-05-05 Goncharov Evgeny S Cleaning and/or grading machine for free-flowing materials
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) * 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
US6339089B2 (en) * 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
AU2002214996B2 (en) 2000-10-12 2007-03-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
NZ530690A (en) 2001-06-22 2005-05-27 Boehringer Ingelheim Pharma Crystalline anticholinergic, proccesses for preparing it and its use for preparing a pharmaceuticaal composition
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (fr) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Composes derives de thienopyrimidine utilises comme inhibiteurs de la prolylpeptidase, inducteurs d'apoptose et agents de traitement anticancereux
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
WO2004096810A1 (fr) * 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines utiles pour le traitement de l'hypertension
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (fr) * 2004-02-27 2005-09-09 Astellas Pharma Inc. Dérivé de pyrimidine bicyclique fondu
DE502006004066D1 (de) 2006-04-19 2009-08-06 Boehringer Ingelheim Pharma Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
BRPI0608387A2 (pt) 2009-12-29
JP2008536890A (ja) 2008-09-11
ATE434620T1 (de) 2009-07-15
KR101335964B1 (ko) 2013-12-04
NO20074615L (no) 2007-11-19
US20090186875A1 (en) 2009-07-23
CA2605161A1 (fr) 2006-10-26
EP1874781A1 (fr) 2008-01-09
JP5021624B2 (ja) 2012-09-12
KR20080004621A (ko) 2008-01-09
US7511045B2 (en) 2009-03-31
MX2007012313A (es) 2007-11-21
US20100197656A1 (en) 2010-08-05
AR053235A1 (es) 2007-04-25
AU2006237354A1 (en) 2006-10-26
UA93872C2 (ru) 2011-03-25
TWI380984B (zh) 2013-01-01
PL1874781T3 (pl) 2009-12-31
PT1874781E (pt) 2009-07-27
ES2328400T3 (es) 2009-11-12
DE102005019201A1 (de) 2006-11-02
DE502006004066D1 (de) 2009-08-06
ZA200707591B (en) 2009-08-26
EA200702200A1 (ru) 2008-04-28
HRP20090395T1 (hr) 2009-08-31
US8354531B2 (en) 2013-01-15
IL186749A (en) 2014-08-31
AU2006237354B2 (en) 2012-03-01
WO2006111549A1 (fr) 2006-10-26
RS51163B (sr) 2010-10-31
SI1874781T1 (sl) 2009-12-31
EP1874781B9 (fr) 2010-09-08
IL186749A0 (en) 2008-02-09
US7723341B2 (en) 2010-05-25
US20070259846A1 (en) 2007-11-08
EP2060575A1 (fr) 2009-05-20
EA013108B1 (ru) 2010-02-26
CY1109348T1 (el) 2014-07-02
EP1874781B1 (fr) 2009-06-24
NZ563488A (en) 2010-04-30
CN101163706A (zh) 2008-04-16

Similar Documents

Publication Publication Date Title
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
FR2896407B3 (fr) Ambulateur
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
DK2004204T3 (da) Behandling af neurodegenerative sygdomme med selenat
DK2035369T3 (da) Terapeutiske
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2107870T3 (da) Lavement med reduceret irritationseffekt til behandling af inflammatorisk tarmsygdom
DK1896077T3 (da) Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2022504T3 (da) Salve til behandling af hæmorider
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
DK2323686T3 (da) Adiponectin til behandling af lungesygdom